Technology
Health
Pharmaceutical

Celyad

$14.16
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$0.11 (0.78%) Today
$0.00 (0.00%) As of 3:59 PM EDT after-hours

Why Robinhood?

You can buy or sell Celyad and other stocks, options, ETFs, and crypto commission-free!

About CYAD

Celyad SA American Depositary Shares, also called Celyad, is a clinical-stage biopharmaceutical company, which engages in the development of cell-based therapies for the treatment of cancer. It operates through the following segments: Cardiology, Immuno-oncology, and Corporate. Read More The Cardiology segment includes the company's Cardiopoiesis, Corquest, and C-Cathez platforms. The Immuno-oncology segment consists of all assets developed based on the CAR-T cell platform. The company was founded by Michel Lussier, William Wijns, and Christian Homsy on July 24, 2007 and is headquartered in Mont-Saint-Guibert, Belgium.

Employees
96
Headquarters
Mont-Saint-Guibert, Walloon Region
Founded
2007
Market Cap
171.97M
Price-Earnings Ratio
Dividend Yield
Average Volume
12.32K
High Today
$14.37
Low Today
$14.00
Open Price
$14.00
Volume
36.21K
52 Week High
$32.18
52 Week Low
$10.59

Collections

Technology
Health
Pharmaceutical
Medical
Biopharmaceutical
Cancer Prevention
2015 IPO
Europe (Non-UK)

CYAD Earnings

Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Q2 2019
Estimated
Actual
Available Aug 26
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.